ClearNote Health, a San Diego-based biotech company focused on early cancer detection, has announced a series of presentations at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, scheduled for October 17–21, 2025. The company will showcase its latest advancements in epigenomic-based liquid biopsy technology, emphasizing its potential to detect deadly cancers at earlier, more treatable stages. Samuel Levy, PhD, Chief Scientific Officer at ClearNote Health, expressed enthusiasm for engaging with the global oncology community, highlighting the company’s progress in transforming early cancer detection and therapy monitoring through innovative epigenomics. The presentations feature research centered on ClearNote Health’s proprietary Virtuoso™ epigenomics platform, which leverages artificial intelligence and bioinformatics to analyze biological differences between cancerous and healthy cells using cell-free DNA (cfDNA) from blood samples. The platform focuses on the epigenetic biomarker 5-hydroxymethylcytosine (5hmC), which changes in cancer and can signal disease presence even before symptoms appear. The company’s Avantect® Pancreatic Cancer and Multi-Cancer Detection Tests are designed to identify cancer early, particularly in high-risk populations, offering a noninvasive alternative to traditional screening methods. Featured scientific posters include the validation of an epigenomic-based multicancer detection test by Stephen R. Quake of Stanford University (Presentation 1745P), and an evaluation of a blood test for early pancreatic cancer detection in individuals with family history or genetic predisposition, led by Randall Brand of the University of Pittsburgh (Presentation 2245P). Another key presentation, by Victoria Goss of the Southampton Clinical Trials Unit (Presentation 2255TiP), outlines the design of the SAFE-D trial, which aims to assess whether targeted surveillance in patients with new-onset diabetes can improve resectability and shift pancreatic cancer to earlier stages. e-Poster presentations further expand on the platform’s capabilities. Stephen R. Quake presents on machine learning algorithms that detect disease biomarkers (1783eP), while Zaed Hamady of University Hospital Southampton explores the relationship between epigenomic signals and circulating tumor allele fraction (246eP). Martin Sjöström from Lund University discusses how tumor fraction contributions to cfDNA are measured in multicancer tests (212eP), and Talia Golan of Sheba Medical Center presents findings on using epigenomic liquid biopsy to monitor response to platinum and PARP inhibitor therapies in patients with germline BRCA-associated pancreatic ductal adenocarcinoma (PDAC) (2270eP). ClearNote Health’s technology is rooted in research from the Stephen Quake laboratory at Stanford University and is built on patented epigenomic methods. The company’s CLIA-certified and CAP-accredited laboratory in San Diego supports clinical development and testing. Its Avantect® tests are designed to detect cancer earlier than conventional methods, potentially improving survival rates by enabling timely intervention. The company continues to advance precision oncology by combining deep epigenomic profiling with AI-driven analytics to provide clinicians with actionable insights into disease progression and treatment response. ClearNote Health’s participation in ESMO 2025 underscores its commitment to translating cutting-edge science into real-world clinical impact. For more information, visit www.avantect.com or www.clearnotehealth.com.